Samuel Lentz to Drug Resistance, Neoplasm
This is a "connection" page, showing publications Samuel Lentz has written about Drug Resistance, Neoplasm.
Connection Strength
0.159
-
Berek JS, Edwards RP, Parker LP, DeMars LR, Herzog TJ, Lentz SS, Morris RT, Akerley WL, Holloway RW, Method MW, Plaxe SC, Walker JL, Friccius-Quecke H, Krasner CN. Catumaxomab for the treatment of malignant ascites in patients with chemotherapy-refractory ovarian cancer: a phase II study. Int J Gynecol Cancer. 2014 Nov; 24(9):1583-9.
Score: 0.121
-
Coleman RL, Brady WE, McMeekin DS, Rose PG, Soper JT, Lentz SS, Hoffman JS, Shahin MS. A phase II evaluation of nanoparticle, albumin-bound (nab) paclitaxel in the treatment of recurrent or persistent platinum-resistant ovarian, fallopian tube, or primary peritoneal cancer: a Gynecologic Oncology Group study. Gynecol Oncol. 2011 Jul; 122(1):111-5.
Score: 0.024
-
Thigpen JT, Blessing JA, Olt G, Lentz SS, Bell J. Cisplatin as second-line therapy in ovarian carcinoma treated initially with single-agent paclitaxel: a Gynecologic Oncology Group study. Gynecol Oncol. 2003 Sep; 90(3):581-6.
Score: 0.014